Infliximab: adverse events as reason for treatment discontinuation

被引：0
作者：
Moustou, A. -E. [1 ]
Papoutsaki, M. [1 ]
Vergou, T. [1 ]
Masouri, S. [1 ]
Sachlas, A. [2 ]
Antoniou, C. [1 ]
机构：
[1] A Sygros Hosp, Dept Dermatol 1, Athens, Greece
[2] Univ Peloponnese, Dept Nursing, Sparta, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
adverse events; infliximab; treatment discontinuation;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P184
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [1] Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events
    Khanna, Reena
    Feagan, Brian G.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (06) : 987 - 997
  • [2] Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
    Subedi, Smriti
    Gong, Yu
    Chen, Youdong
    Shi, Yuling
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 2491 - 2502
  • [3] Postoperative Infliximab Is Not Associated with An Increase in Adverse Events in Crohn’s Disease
    Miguel Regueiro
    Sandra El-Hachem
    Kevin E. Kip
    Wolfgang Schraut
    Leonard Baidoo
    Andrew Watson
    Jason Swoger
    Marc Schwartz
    Arthur Barrie
    Marilyn Pesci
    David Binion
    Digestive Diseases and Sciences, 2011, 56 : 3610 - 3615
  • [4] Risk for Adverse Events and Discontinuation Due To Adverse Events of Ziprasidone Monotherapy Relative to Placebo in the Acute Treatment of Bipolar Depression, Mania, and Schizophrenia
    Gao, Keming
    Pappadopulos, Elizabeth
    Karayal, Onur N.
    Kolluri, Sheela
    Calabrese, Joseph R.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 33 (03) : 425 - 431
  • [5] Postoperative Infliximab Is Not Associated with An Increase in Adverse Events in Crohn's Disease
    Regueiro, Miguel
    El-Hachem, Sandra
    Kip, Kevin E.
    Schraut, Wolfgang
    Baidoo, Leonard
    Watson, Andrew
    Swoger, Jason
    Schwartz, Marc
    Barrie, Arthur
    Pesci, Marilyn
    Binion, David
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (12) : 3610 - 3615
  • [6] Somatization as a predictor of medication discontinuation due to adverse events
    Agosti, V
    Quitkin, FM
    Stewart, JW
    McGrath, PJ
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (06) : 311 - 314
  • [7] Adverse Events Leading to Discontinuation of Phototherapy: An Observational Study
    Belinchon, Isabel
    Sanchez-Pujol, Maria J.
    Docampo, Alejandro
    Cuesta, Laura
    Schneller-Pavelescu, Luca
    Ramos-Rincon, Jose M.
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 (03) : 1 - 6
  • [8] Infliximab in inflammatory bowel disease: attention to adverse events
    Uyanikoglu, A.
    Ermis, F.
    Akyuz, F.
    Pinarbasi, B.
    Baran, B.
    Aydogan, T.
    Demir, K.
    Besisik, F.
    Kaymakoglu, S.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (16) : 2337 - 2342
  • [9] ADVERSE EVENTS ASSOCIATED WITH INFLIXIMAB THERAPY IN A LARGE SINGLE CENTRE UK COHORT
    Sprakes, M.
    Hamlin, P. J.
    Warren, L.
    Greer, D.
    Ford, A. C.
    GUT, 2011, 60
  • [10] Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
    Meinhofer, Angelica
    Williams, Arthur Robin
    Johnson, Phyllis
    Schackman, Bruce R.
    Bao, Yuhua
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2019, 105 : 37 - 43
12345